XLXiaofeng Liu

Xiaofeng Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaofeng Liu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Chunying Tian

    Jilin Cancer Hospital, Changchun, 130021, China

    1 shared publication
  • Hong-Bo Zhang

    Key Laboratory of Zoonosis Research by Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun, China

    1 shared publication
  • Jianhua Li

    School of Vehicle Engineering, Jilin University, Changchun 130025, China

    1 shared publication
  • Nan Zhang

    State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases , Key Laboratory for Zoonosis Research of the Ministry of Education, and College of Veterinary Medicine , Jilin University , Changchun 130062 , China , jlu.edu.cn

    1 shared publication
  • Pengtao Gong

    State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun, PR China

    1 shared publication
  • Ting Li

    Jilin Cancer Hospital, Changchun, 130021, China

    1 shared publication

Latest Publications

  • Open Access

    High prevalence of Pentatrichomonas hominis infection in gastrointestinal cancer patients

    by Nan Zhang, Hongbo Zhang, Yanhui Yu, Pengtao Gong, Jianhua Li, Ziyi Li, Ting Li, Zhanjie Cong, Chunying Tian, Xiaofeng Liu, et al.

    Pentatrichomonas hominis is a flagellated protozoan that inhabits the large intestine of humans. Although several protozoans have been proposed to have a role in cancer progression, little is known about the epidemiology of P. hominis infection in cancer patients. To determine the prevalence of P. hominis in patients with digestive system malignancies, we collected 195 and 142 fecal samples from gastrointestinal cancer patients and residents without any complaints related to the digestive system, respectively. Each sample was detected for the presence of P. hominis by nested PCR amplifying the internal transcribed spacer (ITS) region and partial 18S rRNA gene. A significantly higher prevalence of P. hominis was found in cancer patients than that in the control population (41.54 vs 9.15%, χ2 = 42.84, df = 1, P < 0.001), resulting in a 6.75-fold risk of gastrointestinal cancers (OR: 6.75, 95% CI: 3.55–12.83, P < 0.001). The highest prevalence of P. hominis infection was detected in small intestine cancer patients (60%, OR: 14.88, 95% CI: 0.82–4.58, P = 0.009) followed by liver (57.14%, χ2 = 10.82, df = 1, P = 0.001) and stomach cancer patients (45.1%, χ2 = 31.95, df = 1, P < 0.001). In addition, phylogenetic analysis provided some evidence supporting that human P. hominis infection might derive from animal sources. To our knowledge, this study is the first report presenting the high association between P. hominis and gastrointestinal cancers. Nevertheless, whether there is any possible pathological role of P. hominis infection in cancer patients needs to be further elucidated.